(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

With more diners skipping mains, drinking less and sharing starters because of weight-loss drugs, the traditional ...

TCS partners with Danish Academy of Technical Sciences to combat dengue through technology and citizen engagement: Our Bureau, Bengaluru Friday, March 7, 2025, 12:15 Hrs [IST] Tat ...

Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...

In January, The Wall Street Journal derided Trump’s threat to impose 25 percent tariffs on Canada and Mexico as the opening ...

Novo Nordisk (NVO), the company behind popular diabetes and weight loss medications Ozempic and Wegovy, warned that President ...

Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thurs ...

Novo Nordisk (NVO), the maker of the popular diabetes and weight-loss drugs Ozempic and Wegovy, expects at least some ...